Chugai Pharmaceutical Company Insiders
| CHGCY Stock | USD 20.69 0.17 0.83% |
Chugai Pharmaceutical employs about 43 people. The company is managed by 10 executives with a total tenure of roughly 41 years, averaging almost 4.0 years of service per executive, having 4.3 employees per reported executive. Break down of Chugai Pharmaceutical's management performance can provide insight into the company performance.
| Junichi Ebihara VP VP and General Manager of Legal Department |
| Toshiya Sasai Insider Exec Department |
Chugai |
Chugai Pharmaceutical's latest congressional trading
Congressional trading in companies like Chugai Pharmaceutical, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Chugai Pharmaceutical by those in governmental positions are based on the same information available to the general public.
| 2024-07-09 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
| 2024-05-15 | Representative Josh Gottheimer | Acquired Under $15K | Verify |
Chugai Pharmaceutical Management Team Effectiveness
The company has return on total asset (ROA) of 0.1956 % which means that it generated a profit of $0.1956 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2867 %, meaning that it generated $0.2867 on every $100 dollars invested by stockholders. Chugai Pharmaceutical's management efficiency ratios could be used to measure how well Chugai Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Chugai Pharmaceutical Workforce Comparison
Chugai Pharmaceutical Co is rated below average in number of employees category among its peers. The total workforce of Drug Manufacturers—General industry is currently estimated at about 943,960. Chugai Pharmaceutical adds roughly 43.0 in number of employees claiming only tiny portion of equities under Drug Manufacturers—General industry.
The company has Profit Margin (PM) of 0.3 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.42 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.42. Chugai Pharmaceutical Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Chugai Pharmaceutical Price Series Summation is a cross summation of Chugai Pharmaceutical price series and its benchmark/peer.
Chugai Pharmaceutical Notable Stakeholders
A Chugai Pharmaceutical stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Chugai Pharmaceutical often face trade-offs trying to please all of them. Chugai Pharmaceutical's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Chugai Pharmaceutical's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Shinji Hidaka | Executive Officer, Deputy Chief Director of Sales, Manager of Primary Unit | Profile | |
| Osamu Okuda | Executive Officer, Director of Business Planning | Profile | |
| Yoshiaki Ohashi | Executive Officer, Chief Director of Drug Safety, Manager of Regulatory & Quality Management Unit | Profile | |
| Tetsuya Yamaguchi | Executive Officer, Director of Business Development | Profile | |
| Yoshiyuki Yano | Executive Officer, Director of Human Resources | Profile | |
| Tsunanori Sato | Executive Officer, Chief Director of Sales | Profile | |
| Junichi Ebihara | VP and General Manager of Legal Department | Profile | |
| Toshiaki Itagaki | VP and General Manager of Fin. and Accounting Department | Profile | |
| Toshiya Sasai | Exec Department | Profile | |
| Masahiko Uchida | Gen Department | Profile |
About Chugai Pharmaceutical Management Performance
The success or failure of an entity such as Chugai Pharmaceutical often depends on how effective the management is. Chugai Pharmaceutical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Chugai management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Chugai management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd. CHUGAI PHARMACEUTICAL operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 7664 people.
Please note, the imprecision that can be found in Chugai Pharmaceutical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Chugai Pharmaceutical Co. Check Chugai Pharmaceutical's Beneish M Score to see the likelihood of Chugai Pharmaceutical's management manipulating its earnings.
Chugai Pharmaceutical Workforce Analysis
Traditionally, organizations such as Chugai Pharmaceutical use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Chugai Pharmaceutical within its industry.Chugai Pharmaceutical Manpower Efficiency
Return on Chugai Pharmaceutical Manpower
| Revenue Per Employee | 23.3B | |
| Revenue Per Executive | 100B | |
| Net Income Per Employee | 7B | |
| Net Income Per Executive | 30.3B | |
| Working Capital Per Employee | 10.1B | |
| Working Capital Per Executive | 43.5B |
Additional Tools for Chugai Pink Sheet Analysis
When running Chugai Pharmaceutical's price analysis, check to measure Chugai Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chugai Pharmaceutical is operating at the current time. Most of Chugai Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Chugai Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chugai Pharmaceutical's price. Additionally, you may evaluate how the addition of Chugai Pharmaceutical to your portfolios can decrease your overall portfolio volatility.